The present invention relates to a compounds according to formula I, methods for treating diseases mediated by human immunodeficieny virus by administration of a compound according to formula I and pharmaceutical compositions for treating diseases mediated by human immunodeficieny virus containing a compound according to formula I where R
1
, R
2
, R
3
, R
4
, R
5
, are as defined herein.
The present invention relates to a method of treating an HIV-I infection with a compound according to formula I where R
1
, R
2
, R
3
, R
4
, R
5
, are as defined herein.
Compounds that selectively inhibit the binding of ligands to &agr;4&bgr;1 integrin (VLA-4) and methods for their preparation are disclosed. In one embodiment, compounds of the invention are represented by Formula I:
1
As selective inhibitors of VLA-4 mediated cell adhesion, compounds of the present invention are useful in the treatment of conditions associated with such adhesion, including, but not limited to, such conditions as inflammatory and autoimmune responses, diabetes, asthma, psoriasis, inflammatory bowel disease, transplantation rejection, and tumor metastasis. Also disclosed are pharmaceutical compositions, methods of inhibiting VLA-4 mediated cell adhesion and methods of treating conditions associated with LA-4 mediated cell adhesion, which involve compounds of Formula I.
The present invention provides compounds for treating or preventing an HIV infection, or treating AIDS or ARC comprising administering a compound according to formula I where Ar, R
1
-R
5
, R
11c
and X
1
are as defined herein.
The present invention provides compositions for treating an HIV infection comprising administering a compound according to formula I where Ar, R
1
-R
5
, R
11c
and X
1
are as defined herein with at least one carrier, excipient or diluent.